SCHEMBL507314

SCHEMBL507314

O=C(C1CCCCC1)N(Cc1ccccc1)c1c(Cl)ccc2c1CCNCC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
KDM4E B2RXH2 3/20 0.41
MAPT P10636 1/20 0.41
CNR2 P34972 2/20 0.40
ACHE P22303 1/20 0.39
HTR2B P41595 2/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
NR1H4 Q96RI1 3/20 0.38
ALDH1A1 P00352 3/20 0.38
GAA P10253 1/20 0.38
ALOX12 P18054 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CNR1 P21554 1/20 0.38
AGER Q15109 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Succinic Acid SCHEMBL507540 0.96 LMNA (0.45) LMNASMN1; SMN2MEN1KMT2AKDM4E
Succinic Acid SCHEMBL507602 0.75 HTR2C (0.42) ACHEHTR2BHTR2AHTR2CHTT
SCHEMBL10228225 0.75 HTR2B (0.48) HTR2BHTR2AHTR2C
Succinic Acid SCHEMBL506380 0.75 SLC6A4 (0.40) HTR2BHTR2AHTR2C
SCHEMBL506336 0.74 SLC6A2 (0.45) HTR2BHTR2AHTR2C
Succinic Acid SCHEMBL508327 0.71 HTR2B (0.36) MEN1KMT2AACHEHTR2BHTR2A
SCHEMBL508783 0.68 HTR2B (0.36) LMNASMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL28694741 0.67 MEN1 (0.73) LMNASMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL13768382 0.67 HTR2A (0.43) SMN1; SMN2HTR2BHTR2AHTR2CALDH1A1
Succinic Acid SCHEMBL507114 0.66 SLC6A2 (0.39) MEN1KMT2AKDM4EHTR2BHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720836-B1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS LILLY CO ELI (US) 2014-04-16 EP disclosed
US-8580780-B2 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist ELI LILLY AND COMPANY (US) 2013-11-12 US disclosed
EP-2479168-A1 6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo [d]Azepines as 5-HT2C Receptor Agonists ELI LILLY AND COMPANY (US) 2012-07-25 EP disclosed
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist ELI LILLY AND COMPANY (US) 2012-02-02 US disclosed
US-8022062-B2 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists ELI LILLY AND COMPANY (US) 2011-09-20 US disclosed
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ARRAY BIOPHARMA, INC. 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS HTR2C, HTR5A, HTR4 LMNA 4504/4885SMN1; SMN2 1853/4885MEN1 3996/4885
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist HTR2C, HTR4, HTR1A LMNA 4672/4885SMN1; SMN2 2954/4885MEN1 3801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.